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Background: Carpal tunnel syndrome is known as the most common entrapment neuropathy. Conservative
treatments cannot reduce the symptomatic severity satisfactorily; therefore, effectiveness of Linum usitatissimum L.
(linseed) oil on carpal tunnel syndrome, as a complementary treatment, was evaluated in the current study. Linseed
oil is a well-known preparation in Iranian traditional medicine and its analgesic, anti-inflammatory and anti-oxidative
effects have been shown in previous studies.
Methods: A randomized, double-blind, placebo-controlled clinical trial was conducted. One hundred patients
(155 hands) with idiopathic mild to moderate carpal tunnel syndrome aged between 18 and 65 years old were
randomized in two parallel groups. These two groups were treated during 4 weeks with topical placebo and linseed
oil. In addition, a night wrist splint was prescribed for both groups. Symptomatic severity and functional status were
measured using Boston Carpal Tunnel Questionnaire. In addition, median sensory nerve conduction velocity, motor
distal latency, sensory distal latency and compound latency as electrodiagnostic parameters were measured at
baseline and after the intervention period.
Results: After the intervention, significant improvement was observed regarding Boston Carpal Tunnel
Questionnaire symptomatic severity and functional status mean differences (p <0.001) in the linseed oil group
compared with those in the placebo group. Also, regarding the mean differences of both groups, significant
improvement of nerve conduction velocity of the median nerve was seen in the linseed oil group by a value of
2.38 m/sec (p < 0.05). However, motor distal latency and sensory distal latency of the median nerve showed no
between-group significant changes (p = 0.14 for both items). Finally, compound latency was improved slightly in
the case group, comparing mean differences between the groups (p <0.05). No significant adverse events were
reported from using linseed oil.
Conclusions: It seems that linseed oil could be effective in the management of mild and moderate carpal tunnel
syndrome, especially in improving the severity of symptoms and functional status. In addition, its effect on
electerodiagnostic parameters, especially on the nerve conduction velocity, can be considered as a valuable point.
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Carpal tunnel syndrome (CTS), a condition in which the
median nerve compression occurs, is known as the most
common entrapment neuropathy [1]. Various treatment
options, as surgical and non-surgical, have been suggested
for CTS. Surgery is usually considered for patients with an
experience of conservative treatment failure and those
who have severe CTS [2,3], while non-surgical treatments
are usually prescribed as an initial option for the patients
who do not have any evidence of denervation in elec-
tromyography, cannot undergo surgery, or suffer from
non-constant symptoms of mild to moderate CTS [4,5].
Standard non-surgical treatments vary from exercise and
activity modification to wrist splinting (as the most fre-
quently reported treatment [6]), use of oral medications
like NSAIDs and corticosteroids, and even locally injected
steroids [7,8]. However, conservative treatments cannot
reduce symptomatic severity satisfactorily [9-11]; there-
fore, new conservative treatments are needed to be evalu-
ated in randomized controlled trials.
Nowadays, complementary and alternative medicine
(CAM) is welcomed by general population, governments
and World Health Organization. Easy accessibility, lower
costs and origination of them from nature are the main
causes of this worldwide popularity [12]. Therefore,
CAM treatments can play an important role as new con-
servative treatments for CTS.
Linum usitatissimum L. (from the family Linaceae),
commonly known as flax or linseed, is a herb that is na-
tive to Europe, Asia and Mediterranean regions [13].
Linseed oil or flaxseed oil is obtained from its dried ripe
seeds. In addition to edible uses of this oil, it is known
as an anti-inflammatory [14,15] antioxidant [16,17] and
analgesic [18] oil. Therefore, due to the mentioned bene-
ficial properties, it is used in several studies on a variety
of subjects such as arthritis [15], dermatologic com-
plaints [19], breast cancer [20] and even keratoconjunc-
tivitis [21].
The topical use of linseed oil has been approved for a
variety of skin disorders [22]. For instance, the Brazilian
national pharmacopoeia has approved its topical admin-
istration in cases with pruritus, and in patients of burn
[13]. In addition, some studies examined the topical
usage of this compound in animal model of skin wound
healing, and in the prevention of peri-ileostomy skin ex-
coriation. No toxicity was reported in such studies [23].
Linseed oil could play an anti-inflammatory role when
used by different routes of administration in animal models.
In fact, its inhibition on prostaglandin E2, leukotriene
B4, histamine and bradykinin can make it a potent anti-
inflammatory agent against distinct phases of inflamma-
tion, comparable with standard aspirin [24]. In addition,
it seems that analgesic activity of linseed oil is peripher-
ally mediated [18]. Analgesic activity of linseed oil maybe due to a combination of its inhibitory effect of pros-
taglandin, histamine, bradykinin and acetylcholine [25].
In addition, linseed oil is a well-known and frequently-
used medicine in Iranian traditional medicine (ITM).
According to the most famous and reliable ITM books,
i.e. Avicenna’s Canon of Medicine and Liber Continens
of Rhazes, linseed oil can be used as an analgesic and
anti-fibrosis drug [26,27].
Therefore, according to ITM concepts and some un-
published experiences by experts about potential effect
of linseed oil on CTS and also supporting data about
some properties of linseed oil (e.g. analgesic, antioxidant
and anti-inflammatory), we hypothesized its possible ef-
fect for CTS. Therefore, the current study aimed to as-
sess the effectiveness of topical flaxseed oil in patients
with mild and moderate CTS.
Materials and methods
Study design
The study was designed as a two-arm, randomized,
placebo-controlled, double- blind clinical trial using a
parallel design.
Ethical considerations
The study protocol was in compliance with the Declaration
of Helsinki (1989 revision) and approved by the Local
Medical Ethics Committee of Shiraz University of Medical
Sciences (SUMS) with reference number: CT-92-6709.
The trial was registered in Iranian Registry of Clinical
Trials (registration ID: IRCT2012103111341N1). A writ-
ten informed consent was signed by all of the enrolled
participants.
Preparation of test drug, placebo and wrist splint
Seeds of the test drug were purchased from the local mar-
ket and authenticated by a botanist at Kashan University
of Medical Sciences. A voucher specimen was preserved
for future reference.
The seeds were coarsely ground in an environment of
mild heat, and then cold-pressed (35°C). The extracted
oil was subjected to gas chromatographic (GC) analysis.
The findings revealed the presence of major components
as linolenic acid (54.2%), oleic acid (20.39%), linoleic acid
(12.26%), palmitic acid (5.99%), and stearic acid (5.7%).
Nitrogen purging was carried out to avoid oxidation. In
addition, the bottles had no head space (the oil was filled
to the bottle brim).
Pharmaceutical graded paraffin was considered as the
placebo. In addition, standard coloring agent in a little
amount and standard range was used to make paraffin’s
color similar to that of the linseed oil.
A wrist splint (Dr. K. H.®) immobilized the wrist in an
extension position (external angle: 20° and internal angle:
5°). The splint was made of 5-mm medical foam, lined
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addition, it had three adjustable Velcro fastenings on its
dorsal side (Figure 1).
Inclusion and exclusion criteria
Patients (from the Outpatient Clinic of Shahid Faghihi
Hospital, an academic teaching center, affiliated with
SUMS) with suspected CTS (according to history and
physical examination) were selected after electrophysio-
logic confirmation study.
Detailed inclusion and exclusion criteria are shown in
Table 1. The eligibility criteria included briefly: patients
of both sexes aged between 18 and 65 years old, with
idiopathic mild and moderate CTS. Some of the most
important exclusion criteria were: coexisting serious ill-
ness, rheumatoid arthritis, CTS related to systemic dis-
eases and pregnancy. In addition, the patients were
excluded if they had previous surgery for CTS or intra-
carpal steroid injections.
Electrodiagnosis
The electrophysiologic assessments were performed by a
“MEDLEC SYNERGY VIASIS” electromyography device
with two 6 mm felt tips bar electrodes as the stimulators
and recorders (diameter of pads 23 mm apart). Median
distal motor latency was measured by a bipolar stimu-
lating electrode at the wrist and a bipolar surface-
recording located on the abductor pollicis brevis muscle
(8 cm from stimulus electrodes at the wrist). Antidromic
sensory nerve action potentials evoked at the wrist were
recorded from the middle finger. Standard distances
(7 cm from recorder, at mid palm and 14 cm from re-
corder at wrist) were kept between the stimulator and
recorder electrodes. For recording the compound nerve
action potential, stimulation at mid palm and recording
at wrist (7 cm apart) was performed. In addition, using aFigure 1 A photograph of fabricated wrist splint that was
prescribed for all of the participants (dorsal view).concentric needle electrode, electromyography was per-
formed on the abductor pollicis brevis muscle. We defined
denervation as sustained, abnormal spontaneous activity.
This ranged from 0 to 4+, in the form of positive waves or
fibrillations. The skin temperature during all of the elec-
trodiagnostic studies was at least 31°C and all of the as-
sessments were carried out in a similar constant room
temperature between 23°C and 25°C. In addition, due to
the possibility of diurnal variation in clinical and electro-
physiologic assessments [28], all of the patients were
assessed at the follow up visit at a similar time of the day
as the first session. In addition, the patients were assessed
on their visits by the same authors (K.H and A.A) who
performed clinical examinations and electrodiagnostic




All of the patients were prescribed to use the wrist splint
during the study period. In fact, the test drug and pla-
cebo were added to this standard treatment. The wrist
splint prescription was night-only because of symptoms
usually worsening at night, in addition to obtaining a
higher compliance, considering the patient’s concern
about splint’s interference with his/her daily activities.
Placebo and test drug
Both of the drug and placebo were prescribed to be used
in the morning and evening time for a period of 4 weeks,
5 drops per use, topically on the palmar wrist territory.
The patients were advised not to massage the mentioned
zone.
Outcome assessment
Boston Carpal Tunnel Questionnaire (BCTQ), as a self-
administered, validated measurement, was the primary
outcome measure. The BCTQ assesses symptom severity
score (BCTQ SYMPT) and functional status score
(BCTQ FUNCT). These scores are evaluated by an
eleven-item scale and an eight-item scale, respectively
[29]. The items of each scale consist of multiple-choice
responses from 1 (as the mildest) to 5 (as the most se-
vere). The BCTQ SYMPT and FUNCT are calculated as
the mean of the scores for the individual items.
We used the Persian version of BCTQ that was vali-
dated previously, showing to have a reasonable reliability,
sensitivity and internal consistency [30].
Secondary outcome measures were median nerve sen-
sory distal latency (SDL), sensory nerve conduction vel-
ocity (NCV), motor distal latency (MDL) and compound
latency (CL).
At the beginning of the enrollment and after 4 weeks
of intervention, the data related to both primary and
Table 1 Inclusion and exclusion criteria
Inclusion criteria Patients of both sexes aged between 18 and 65 years
old willing to sign the informed consent form
Clinical symptoms and signs of CTS (at least 2






- Positive Phalen test
- Positive Tinnel test
Electrodiagnostic evidence of mild and moderate
idiopathic CTS, including:
● SDL > 3.7 m Sec
● SNCV < 40 m/Sec
● MDL > 4.2 m Sec
● CL > 2.4 m Sec
Exclusion criteria Positive history of hypersensitivity to linseed oil
Inability of data gathering forms completion (such as
cognitive impairment or language problem)
Patients with severe CTS, clinical and electrodiagnostic
evidence including (if any of these evidences was found):
– Thenar atrophy
–Fibrillation potentials or reinnervation on needle
EMG of APB muscle
–Electrophisiologic study:
● SDL > 5.3 m Sec OR Absent
● SNCV < 28 m/Sec
● MDL > 6.5 m Sec OR Absent
● CL > 3.2 m Sec
Coexisting cervical radiculopathies, brachial plexopathies
or more proximal median mononeuropathies
Clinical and electrophysiological signs of polyneuropathy
Rheumatologic diseases, like RA, systemic sclerosis,
SLE and amyloidosis
Endocrinologic diseases, such as DM and hypothyroidism
Conditions that can mimic CTS such as multiple sclerosis
Pregnancy
Coexisting serious illness, such as renal and heart failure
Recent or ongoing inevitable use of corticosteroids
or analgesics
Previous surgery for CTS
Intra-articular injection within the previous 6 months
Positive history of severe trauma or fracture of wrist bones
SDL: sensory distal latency; SNCV: sensory nerve conduction velocity; MDL:
motor distal latency; CL: compound latency; EMG: electromyography; APB:
abductor policis brevis; RA: rheumatoid arthritis; SLE: systemic lupus
erythematosus; DM: diabetes mellitus.
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corded on the patient’s data form. We excluded the pa-
tients who had recent or ongoing inevitable use of
corticosteroids or analgesics; however, the included pa-
tients were asked to record their use of analgesics as the
rescue drug.
Randomization, blinding and concealment of allocation
The eligible patients were randomly allocated to two
parallel groups, the drug and placebo groups, by the sec-
retary of the clinic. She was trained and instructed to
use a block-randomization list (non-stratified, with the
same block lengths, generated by computer) sequentially.
In the case of patients affected by CTS bilaterally, both
wrists were allocated to the same intervention (i.e. drug
or placebo). The physicians, researchers, and statisticians
were blind to the allocation of patients. Moreover, due
to the same shape and size of the drug and placebo con-
tainers and similarity in color, the patients were blind to
their allocation.
Statistical analysis
The intention-to-treat population used in all of the ana-
lyses included all randomized patients who completed
their follow up, whether adhering completely to the clin-
ical trial protocol or not.
Demographic and clinical characteristics of the partici-
pants were shown as the mean ± standard deviation (SD)
for continuous variables. Differences of pre- and post-
treatment were reported as mean and 95% confidence
intervals.
Normality for continuous variables was checked using
Kolmogorov-Smirnov test. Data were analyzed using Chi-
square test, independent and paired samples t-test, and
Mann–Whitney test. P values less than 0.05 were consid-
ered statistically significant.
Results
The first enrollment was done in October 2013 and the
last patient’s follow-up was completed in January 2014.
A total of 119 patients (183 hands) were assessed for eli-
gibility, and finally 100 patients (155 hands) who were
eligible and gave their written informed consent were
randomly assigned to drug and placebo groups (79 and
76 hands for placebo and drug, respectively). Sixty four
hands in the linseed oil group and 68 hands in the pla-
cebo group completed the study. Detailed description of
the patients’ enrolment, randomization and outcomes
are outlined in Figure 2.
The baseline demographic and clinical characteristics
of the patients are shown in Table 2. No significant differ-
ences with regard to age, gender, duration of symptoms
and BMI were observed between two arms. Additionally,
Assessment for eligibility 
119 patients 
(n=183 hands)
Allocated to linseed group
Received allocated intervention 
(n=76 )
Did not receive linseed  (n=0)
Included in Analysis (n=64 hands)
Lost to follow-up (2 migration, 8 




Allocated to placebo group
Received allocated intervention 
(n=79 )
Did not receive placebo(n=0)
Included in Analysis (n=68 hands)





25 were ineligible 
3 refused to participate 
Figure 2 The trail flowchart.
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similar in both groups.
The patients were asked about their adherence to the
study protocol at the follow-up visit. In the linseed oil
group, only 3 patients reported some missing doses of oil
and 2 patients had not used the splint as it was prescribed.
In addition, in the placebo group 4 and 2 patients reported
some forgotten doses of oil and inappropriate use of
splint, respectively. However, all of them were analyzed inTable 2 Baseline demographic and clinical characteristics of p
Variable Placebo group (n = 79)
Age (years), Mean(±SD) 45.01(±8.71)
Male/female (n) 4/64
Duration(months), Mean(±SD) 13.66(±13.45)
BMI (kg/m2), Mean(±SD) 27.03(±3.25)
BCTQ SYMPT (pts), Mean(±SD) 2.75(±0.62)
BCTQ FUNCT (pts), Mean(±SD) 2.41(±0.74)
Median NCV (m/sec), Mean(±SD) 36.27(±4.29)
Median MDL (msec), Mean(±SD) 4.16(±0.20)
Median CL (msec), Mean(±SD) 2.533(±0.17)
Median SDL (msec), Mean(±SD) 3.99(±0.26)
SD: standard deviation, BMI: body mass index, BCTQ: Boston Carpal Tunnel Questio
nerve conduction velocity, MDL: motor distal latency, CL: compound latency, SDL: sthe predetermined groups. Additionally, according to the
patients’ report, no rescue drug was used by them in each
group.
Table 3 shows a full description of each outcome
measurement changes, considering before and after trial,
as well as mean differences in each group. Comparison
of the mean differences between the groups showed a
significant improvement in BCTQ SYMPT and FUNCT
of the linseed oil group, after a 4 week period ofarticipants in the two groups of linseed oil and placebo











nnaire, SYMPT: symptom severity, FUNCT: functional status, pts: points, NCV:
ensory distal latency.
Table 3 Changes in BCTQ symptoms, BCTQ function and electrophysiologic measurements, comparing mean values





p-value Statistical test Mean difference p-value Statistical test
BCTQ SYMPT Linseed oil 2.74 ± 0.75 1.90 ± 0.54 <0.0001 Paired t-test 0.83 ± 0.59 (CI 95% 0.69–0.99) <0.001 Independent t-test
Placebo 2.75 ± 0.62 2.59 ± 0.75 <0.0001 Paired t-test 0.16 ± 0.48 (CI95% 0.05–0.28)
BCTQ FUNCT Linseed oil 2.61 ± 0.71 2.17 ± 0.71 <0.0001 Paired t-test 0.44 ± 0.5 (CI 95% 0.32–0.56) <0.001 Independent t-test
Placebo 2.41 ± 0.74 2.59 ± 0.80 0.024 Paired t-test - 0.18 ± 0.5 (CI 95% -0.31- -0.07)
Median NCV Linseed oil 35.54 ± 3.81 37.92 ± 6.23 0.007 Paired t-test 2.38 ± 6.78 (CI 95% 0.72–4.04) 0.034 Independent t-test
Placebo 36.27 ± 4.29 36.22 ± 6.07 0.57 Paired t-test 0.04 ± 6.21 (CI 95% -1.52–1.43)
Median MDL Linseed oil 4.20 ± 0.34 4.06 ± 0.33 <0.0001 Paired t-test 0.14 ± 0.29 (CI 95% 0.07–0.21) 0.140 Independent t-test
Placebo 4.16 ± 0.20 4.10 ± 0.35 <0.0001 Paired t-test 0.06 ± 0.32 (CI 95% -0.02–0.14)
Median CL Linseed oil 2.52 ± 0.14 2.43 ± 0.23 0.004 Paired t-test 0.09 ± 0.21 (CI 95% 0.03–0.15) 0.044 Independent t-test
Placebo 2.53 ± 0.17 2.54 ± 0.32 0.145 Paired t-test −0.008 ± 0.28 (CI 95% -0.08–0.06)
Median SDL Linseed oil 3.95 ± 0.43 3.82 ± 0.34 0.032 Paired t-test 0.12 ± 0.45 (CI 95% 0.01–0.24) 0.144 Independent t-test
Placebo 3.99 ± 0.26 3.97 ± 0.36 0.053 Paired t-test 0.02 ± 0.36 (CI 95% -0.07–0.11)
SD: standard deviation, BCTQ: Boston Carpal Tunnel Questionnaire, SYMPT: symptom severity, FUNCT: functional status, NCV: nerve conduction velocity,
MDL: motor distal latency, CL: compound latency, SDL: sensory distal latency, CI 95%: 95%confidence interval
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were 0.83 (CI 95% 0.69 – 0.99) and 0.44 (CI 95% 0.32 –
0.56), respectively.
In addition, regarding mean differences of both groups,
a significant improvement of NCV of the median nerve
was seen in the linseed oil group by a difference of
2.38 m/sec (CI 95% 0.72 – 4.04, p = 0.034). However,
mean differences of the median nerve’s MDL and SDL
in the linseed oil group showed no significant differences
as compared with the placebo group (p = 0.14 for both
items). Finally, comparison of the mean differences be-
tween the groups revealed a slight improvement in the CL
of the linseed oil group (CI 95% 0.03 – 0.15, p = 0.044).
Safety and tolerability
The patients in both groups were asked about positive
history of dermal reactions to any topical products and
if it was positive, they were instructed to test the pre-
scribed oil on their arm for the first use.
Linseed oil was well tolerated by patients. No serious
adverse effects, neither local nor systemic, were reported
in the treated group. Likewise, no additional neuropathy
or local neural injury was noted in electrophysiologic
tests on the follow-up visit.
Discussion
To the best of our knowledge, the present study is the
first research to evaluate the effects of linseed oil on
CTS. However, this herbal preparation has an ancient
history of administration for different disorders, dating
back to more than 10 centuries ago in ITM [22,23]. Lin-
seed oil is a rich source of α‐linolenic acid that has been
proved to possess noticeable anti-inflammatory activity[31]. In addition, further studies have confirmed its anti-
inflammatory [14,15], antioxidant [16,17], and analgesic
[18] properties.
Different mechanisms for its anti-inflammatory effects
are explained. The linseed oil inhibits prostaglandin E2,
leukotriene B4, histamine and bradykinin-induced inflam-
mation. The oil also inhibits arachidonic acid-induced in-
flammation. It shows inhibition of both cyclooxygenase
and lipoxygenase pathways of arachidonate metabolism
[18]. Similar to other multiple herbal formulations, anesthetic
properties of topical use of linseed is also shown in animal
models [32]. According to the important role of inflamma-
tory and oxidative processes in the pathophysiology of
CTS [33,34], its significant effect on improving symptom-
atic and functional status of our patients, and slightly but
statistically significant improving effect on NCV and CL
can be explained partially.
Although no previous study on the efficacy of linseed
oil on CTS was found, some studies evaluated other herbal
preparations in the management of CTS. In a study by
Zhang et al. on the efficacy of Chinese herbal therapy on
CTS comparing with two other groups, 22 patients who
received this therapy had a superior benefit on their visual
analogue scale (VAS) score than the splint group and no
significant changes of electromyography was shown [35].
Our results are in compliance with symptomatic relief of
their patients with a common aspect about the presence
of oleic and linoleic acid in some of these used herbs.
However, this study was not blind and had a small sample
size. Furthermore, they did not assess the effects of a spe-
cific herb with determined constituents and they used an
uncommon drug delivery system (steaming and washing).
Also, Branco et al. published an open protocol study in
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failure, were treated by a two-stage protocol. They were
treated primarily with a specific laser acupuncture and
microamps transcutaneous electrical nerve stimulation
and secondarily with herbal formulas and supplements in
a case-by-case manner [36]. Similar to our trial, this small
size study (only 36 patients) showed a significant effect on
symptomatic improvement (91.6%). However, the com-
plexity of their management can result in practical diffi-
culties during usage.
Another notable study, which was conducted by
Eftekharsadat et al. on two groups of 30 patients, evalu-
ated the efficacy of topical Eremostachys laciniata on
CTS. This medicinal herb has been shown to have anti-
inflammatory and antioxidant properties, like linseed
oil. They showed significant improvement on palmar
prehension and VAS of pain, compared with placebo.
However, this plant had a local popularity, and no sig-
nificant effect on electrodiagnostic criterion was re-
ported [37].
There is also a case-series carried out by Jung et al.
that assessed the usefulness of Jackyakamcho-tang on
muscle spasm and pain on 81 patients complaining
about these symptoms. The usefulness was reported as
72.8% for treating CTS (where only 11 CTS patients had
been included). But, unlike the safety of linseed oil, they
reported adverse effects in 11.1% of the total patients,
3.7% of which were severe [38].
In regard of the topical treatment for CTS, few studies
were found. Of those, Jazayeri et al. published a clinical
trial evaluating EMLA cream which had some beneficial
effects [39]. However, this trial was not blind and EMLA
cream was not as cheap and available as linseed oil.
According to ITM, patient’s temperament can affect
some herbal medicine effects [40]. Therefore, as a minor
assessment we evaluated the participant’s temperament.
However, no relationship was found between the partici-
pant’s temperament and outcome measures. It could be
explained in some ways. The used questionnaire was not
designed for our target population [41] and the drug effects
are possibly independent of the patient’s temperament.
Linseed oil has some important advantages as feasibility
of use as a topical drug and no disturbance of ordinary
daily activities (comparable with treatments such as wrist
splint), conservative and noninvasive nature (regarding
some invasive options such as surgery), price of the oil
(1 $ for a 40 cc bottle that is adequate for a one month
use), worldwide availability, and its acceptable and signifi-
cant effects, especially on symptomatic and functional sta-
tus and even on some electrodiagnostic parameters.
Study limitations
Here we should highlight some limitations that we have
faced with in this trial. First, insufficient number of maleparticipants (only about 10.5% of our patients), which
can affect the generalizability of our findings. In fact, ac-
cording to previous epidemiologic studies, about 30% of
CTS encounters were attributable to males [42]. Indeed,
this is a common problem in several trials on CTS, even
with male samples as small as 0-10% [43-45].
Second, as regards to reliable and valid assessment by
BCTQ about subjective functional status of patients, ob-
jective functional outcome measures such as dynamom-
eter findings could offer more reliable results.
The other important issue is to determine the trans-
dermal penetration of the linseed oil. In this respect, the
measurement of transdermal permeation of the oil and
its consequent absorption into the systemic circulation
can be the subject of the future studies.
And finally, the short term follow-up is another limita-
tion. However, this is partially related to our aim as
evaluation of efficacy and safety of topical linseed oil as
a new complementary treatment for the management of
CTS. It is also considerable that herbal medicaments
might show delayed pharmacological activity. Thus, long
term assessment possibly leads to better results. On the
other side, unwanted effects may also be revealed in long
term evaluation.
Conclusion
It seems that linseed oil could be effective as an adjunctive
therapy in the management of mild and moderate CTS,
especially in improving the severity of symptoms and
functional status. In addition, its effect on electerodiagnos-
tic parameters, especially on NCV, can be considered as a
valuable point.
It is, therefore, suggested that further trials of longer
follow-up and larger sample size, including appropriate
male/female ratio and objective functional status out-
come measures are needed to confirm the value of lin-
seed oil as a good choice for CTS and for evaluation of
the involved mechanisms. Moreover, other easily applic-
able pharmaceutical dosage forms (such as ointment,
cream, gel and patch form) can be considered in future
studies.
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